India Sets Pharma Export Growth Targets - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

India Sets Pharma Export Growth Targets



Untitled Document India Brand Equity Foundation (IBEF) and Pharmexcil reported at CPhI Worldwide the country’s plans for growth and its commitment to lowering the cost of medicines globally. In 2012, India was recognized by UNICEF’s Supply Annual Report as the largest supplier of generics globally.

This year India’s pharma exports stands at $14.7 billion (2012-2013), registering a growth rate of 11%, with 55% of exports heading to highly regulated western markets. India is working to improve access to life-saving medicines in developing economies and the government has set a target of $25 billion for pharmaceutical exports by 2016.

The government of India has made tax breaks available to the pharmaceutical sector and a weighted tax deduction of 150% for any R&D expenditure incurred. They have also introduced 19 special economic zones to help stimulate pharma sector investment across the country. As a result of these initiatives, it is predicted that R&D expenditure will continue to grow at an annualized rate of nearly 20% for the next few years. In addition, the Department of Pharmaceuticals has set aside $478.4 million to set up 10 more National Institute of Pharmaceutical Education and Research (NIPER).

Source: India Brand Equity Foundation

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
27%
Breakthrough designations
9%
Protecting the supply chain
41%
Expedited reviews of drug submissions
9%
More stakeholder involvement
14%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests

Click here